Regulation of cardiac miR-208a, an inducer of obesity, by rapamycin and nebivolol

Obesity

Volumn 23, Issue 11, 2015, Pages 2251-2259

  Gul, Rukhsana ^a,b,c   Mahmood, Abuzar ^a,b   Luck, Christian ^a,b   Lum Naihe, Kelly ^a,b   Alfadda, Assim A ^c   Speth, Robert C ^d,e   Pulakat, Lakshmi ^a,b  

^a University of Missouri   (United States)

^b Research Service   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II I 125; APOCYNIN; LEPTIN; LOSARTAN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MEDIATOR COMPLEX; MEDIATOR COMPLEX 13; MICRORNA; MICRORNA 208A; NEBIVOLOL; RAPAMYCIN; UNCLASSIFIED DRUG; MIRN208 MICRORNA, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; HEART MUSCLE CELL; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WEIGHT GAIN; ZUCKER FATTY RAT; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; ZUCKER RAT;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; GENE EXPRESSION REGULATION; MALE; MEDIATOR COMPLEX; MICE; MICRORNAS; MYOCYTES, CARDIAC; NEBIVOLOL; OBESITY; RATS; RATS, ZUCKER; SIGNAL TRANSDUCTION; SIROLIMUS; WEIGHT GAIN;

EID: 84946490012     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21227     Document Type: Article

References (37)

1. How the world could better fight obesity. McKinsey Global Institute Web site. Available at: http://www.mckinsey.com/insights/economic-studies/how-the-world-could-better-fight-obesity#sthash.FLlIQ1a7.dpuf
2. Raymond T, Raymond R, Lincoff AM., Management of the patient with diabetes and coronary artery disease: a contemporary review. Future Cardiol 2013; 9: 387-403.
3. Cleland SJ., Cardiovascular risk in double diabetes mellitus-when two worlds collide. Nat Rev Endocrinol 2012; 8: 476-485.
4. Pulakat L, DeMarco VG, Ardhanari S, et al., Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol 2011; 301: R885-R895.
5. Callis TE, Pandya K, Seok HY, et al., MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009; 119: 2772-2786.
6. van Rooij E, Quiat D, Johnson BA, et al., A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009; 17: 662-673.
7. Montgomery RL, Hullinger TG, Semus HM, et al., Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 124: 1537-1547.
8. Satoh M, Minami Y, Takahashi Y, Tabuchi T, Nakamura M., Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail 2010; 16: 404-410.
9. Grueter CE, van Rooij E, Johnson BA, et al., A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 2012; 149: 671-678.
10. Frishman WH, Saunders E., β-adrenergic blockers. J Clin Hypertens (Greenwich) 2011; 13: 649-653.
11. Ginelli P, Bella JN., Treatment of diastolic dysfunction in hypertension. Nutr Metab Cardiovasc Dis 2012; 22: 613-618.
12. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al., Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107: 2747-2752.
13. Boxall BW, Clark AL., Beta-blockers and weight change in patients with chronic heart failure. J Card Fail 2012; 18: 233-237.
14. Gul R, Demarco VG, Sowers JR, Whaley-Connell A, Pulakat L., Regulation of overnutrition-induced cardiac inflammatory mechanisms. Cardiorenal Med 2012; 2: 225-233.
15. Ladage D, Reidenbach C, Rieckeheer E, Graf C, Schwinger RH, Brixius K., Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J Cardiovasc Pharmacol 2010; 56: 275-281.
16. Sengupta S, Peterson TR, Sabatini DM., Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40: 310-322.
17. Zoncu R, Efeyan A, Sabatini DM., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
18. Arnold N, Koppula PR, Gul R, Luck C, Pulakat L., Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One 2014; 9: e103284.
19. Yang SB, Tien AC, Boddupalli G, Xu AW, Jan YN, Jan LY., Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 2012; 75: 425-436.
20. Deblon N, Bourgoin L, Veyrat-Durebex C, et al., Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 2012; 165: 2325-2340.
21. Chiarini F, Evangelisti C, McCubrey JA, Martelli AM., Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 2015; 36: 124-135.
22. Lamming DW, Ye L, Sabatini DM, Baur JA., Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 2013; 123: 980-989.
23. White SM, Constantin PE, Claycomb WC., Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 2004; 286: H823-H829.
24. Matute C, Pulakat L, Río C, Valcárcel C, Miledi R., Properties of angiotensin II receptors in glial cells from the adult corpus callosum. Proc Natl Acad Sci USA 1994; 91: 3774-3778.
25. Hunter WM, Greenwood FC., Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962; 194: 495-496.
26. Speth RC, Harding JW., Radiolabeling of angiotensin peptides. In:, Wang DH, editor. Methods in Molecular Medicine: Angiotensin Protocols, Vol. 55. Totowa NJ: Humana Press; 2001: 275-295
27. Ribeiro RF, Jr, Potratz FF, Pavan BM, et al., Carvedilol prevents ovariectomy-induced myocardial contractile dysfunction in female rat. PLoS One 2013; 8: e53226.
28. Gao Y, Vanhoutte PM., Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59: 16-21.
29. Maffei A, Di Pardo A, Carangi R, et al., Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 2007; 50: 652-656.
30. Chen Z, Peng IC, Sun W, et al., AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 2009; 104: 496-505.
31. Hodis J, Vaclavíková R, Farghali H., Beta-3 agonist-induced lipolysis and nitric oxide production: relationship to PPARgamma agonist/antagonist and AMP kinase modulation. Gen Physiol Biophys 2011; 30: 90-99.
32. Erickson CE, Gul R, Blessing CP, et al., The β-blocker nebivolol is a GRK/β-arrestin biased agonist. PLoS One 2013; 8: e71980.
33. Chiang GG, Abraham RT., Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005; 280: 25485-25490.
34. Fonarow GC., Diabetes medications and heart failure: recognizing the risk. Circulation 2014; 130: 1565-1567.
35. Yao H, Han X, Han X., The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway. Am J Cardiovasc Drugs 2014; 14: 433-442.
36. Sciarretta S, Volpe M, Sadoshima J., Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res 2014; 114: 549-564.
37. Kubli DA, Gustafsson AB., Cardiomyocyte health: adapting to metabolic changes through autophagy. Trends Endocrinol Metab 2014; 25: 156-164.